Companies › Pharmazz
3 active drug programs in 5 registered trials: 2 Phase 4, 2 Phase 2, 1 Phase 3; Other, Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Centhaquine (LYFAQUIN™) α2B-adrenergic receptor agonist (venous) and α2A-adrenergic receptor agonist (arterial); e | ADRA2B, ADRA2A | Phase 4 | Hypovolemic Shock | Nov 2026 |
| Sovateltide ETB receptor agonist | EDNRB | Phase 4 | Acute Cerebral Ischemia; Acute Ischemic Stroke; Hypoxic-Ischemic Encephalopathy | Nov 2026 |
| PMZ-1620 Endothelin-B receptor agonist | EDNRB | Phase 2 | Acute Spinal Cord Injury | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04054414 | PMZ-1620 | Phase 2 | Acute Spinal Cord Injury | Neurology | Jun 2026 |
| NCT05956418 | Centhaquine (LYFAQUIN™) | Phase 4 | Hypovolemic Shock | Other | Nov 2026 |
| NCT05514340 | Sovateltide | Phase 2 | Hypoxic-Ischemic Encephalopathy | Other | Nov 2026 |
| NCT05955326 | Sovateltide | Phase 4 | Acute Cerebral Ischemia | Neurology | Dec 2026 |
| NCT05691244 | Sovateltide | Phase 3 | Acute Ischemic Stroke | Neurology | Sep 2027 |
Chongqing Claruvis Pharmaceutical Harmony Biosciences Management argenx Epygenix Incepta Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.